476 results on '"Fagotti Anna"'
Search Results
2. Feasibility and operative outcomes of surgery in the liver area in advanced ovarian cancer
3. Predicting Surgical Outcome
4. Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives
5. Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients
6. Consistent data about the predictive factors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers in two large independent datasets.
7. Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?
8. Laparoscopic Adnexal Surgery
9. The immunolocalization of adiponectin and its receptors in the testis of the frog Pelophylax bergeri
10. Survival associated with the use of one-step nucleic acid amplification (OSNA) to detect sentinel lymph node metastasis in cervical cancer
11. ASO Visual Abstract: Expanding the Use of HIPEC in Ovarian Cancer at the Time of Interval Debulking Surgery to FIGO Stage IV After Six Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis of Perioperative and Oncologic Outcomes
12. Patient satisfaction with ultrasound, whole-body CT and whole-body diffusion-weighted MRI for pre-operative ovarian cancer staging: a multicenter prospective cross-sectional survey
13. How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature
14. ASO Author Reflections: Expanding the Use of HIPEC in Ovarian Cancer at Time of Interval Debulking Surgery
15. Distribution and prognostic role of BRCA status in elderly ovarian cancer patients
16. New windows of surgical opportunity for gynecological cancers in the era of targeted therapies
17. Expanding the Use of HIPEC in Ovarian Cancer at Time of Interval Debulking Surgery to FIGO Stage IV and After 6 Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis on Perioperative and Oncologic Outcomes
18. Retroperitoneal schwannoma during pregnancy: A case report and practice-based overview
19. The new robotic system HUGO RAS for gynecologic surgery: First European experience from Gemelli Hospital
20. Epithelial ovarian cancer and brain metastases: might theBRCAstatus, PARP inhibitor administration, and surgical treatment impact the survival?
21. Predictive factors of surgical complications after pelvic exenteration for gynecological malignancies: a large single-institution experience
22. ASO Visual Abstract: Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor—A Single-Institution Experience (ID:PARROT Trial)
23. Low-gradeversushigh-grade serous ovarian cancer: comparison of surgical outcomes after secondary cytoreductive surgery
24. Highlights from the 24th European Congress on Gynaecological Oncology in Istanbul: an ENYGO-IJGC Fellows compilation
25. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor: A Single-Institution Experience (ID: PARROT Trial)
26. ASO Author Reflections: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Platinum-Resistance Ovarian Cancer Patients
27. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in patients with ovarian cancer: A systematic review
28. Lymph node staging in grade 1–2 endometrioid ovarian carcinoma apparently confined to the ovary: Is it worth?
29. Corrigendum to “Robotic surgery in ovarian cancer” [Best Pract Res Clin Obst Gynaecol Volume 90 (August 2023) 102391]
30. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): New Approaches and Controversies on the Treatment of Advanced Epithelial Ovarian Cancer—Systematic Review and Meta-Analysis
31. TP022/#997 Sentinel-node biopsy in early stage ovarian cancer: preliminary results of a prospective multicentre study (SELLY)
32. PO014/#364 Laparoscopic cytoreduction after neoadjuvant chemotherapy (LANCE): feasibility phase of a randomized trial
33. Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients – An international pooled analysis of three ESGO accredited centres
34. SENTINEL-NODE BIOPSY IN APPARENT EARLY STAGE OVARIAN CANCER: FINAL RESULTS OF A PROSPECTIVE MULTICENTRE STUDY (SELLY)
35. Prediction of the Risk of Malignancy of Adnexal Masses during Pregnancy Comparing Subjective Assessment and Non-Contrast MRI Score (NCMS) in Radiologists with Different Expertise
36. International expert consensus on the surgical anatomic classification of radical hysterectomies
37. Extra-cranial meningioma associated with relapse of immature ovarian teratoma
38. Hyperthermic intraperitoneal chemotherapy for ovarian cancer: long-term findings from the OVHIPEC-1 trial
39. Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer
40. Sentinel lymph node biopsy in ovarian cancer: more questions than certainties
41. Laparoscopic transabdominal cerclage in pregnant woman after fertility sparing treatment for early-stage cervical cancer: operative technique in ten steps.
42. #759 Comprehensive cancer genomic profiling in matched primary tumor and brain metastasis samples of ovarian cancer patients: a single-institution case series
43. #820 Survival associated with the use of one-step nucleic acid amplification (OSNA) to detect SLN metastasis in cervical cancer
44. #485 The impact of previous maintenance therapy on disease presentation and secondary cytoreductive perioperative outcomes in platinum sensitive ovarian cancer recurrent patients
45. #385 Patient satisfaction with ultrasound, CT and WB-DWI/MRI for preoperative ovarian cancer staging: a multicenter prospective survey
46. #765 Efficacy of maintenance with PARPi in advanced ovarian cancer according to the type of BRCA mutation
47. #818 Genetic implications of a comprehensive cancer genome profiling programme in a monoinstitutional study: focus on gynecological cancers
48. #881 The NUVOLA TRIAL: neoadjuvant chemoteraphy in unresectable ovarian cancer with olaparib and weekly carboplatin plus paclitaxel. A phase II open-label multi-centre study
49. #709 The effects of niraparib dose reduction on long-term outcomes in ovarian cancer patients: a large retrospective, observational study
50. #620 Platinum may still be an option for epithelial ovarian cancer patients relapsing within 6 months after first line standard chemotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.